Version history

{
  "session_id": "sess_SDA-BIOMNI-GENE_COE-55fc5237",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "mini-max",
  "action": "synthesize",
  "content": "\n\n{\"ranked_hypotheses\": [{\"title\": \"Conserved Synaptic-Mitochondrial Module in AD-Vulnerable Regions\", \"description\": \"WGCNA-derived co-expression module containing synaptic vesicle genes (SYN1, SYN2, SYT1) and mitochondrial OXPHOS components (MT-ND1, MT-CO1, UQCRC1) consistently upregulated across prefrontal cortex, hippocampus, and entorhinal cortex in AD, reflecting compensatory synaptic hyperactivity paired with mitochondrial stress response.\", \"target_gene\": \"Module hub genes: SYN1, UQCRC1\", \"composite_score\": 0.32, \"evidence_for\": [{\"claim\": \"Synaptic and mitochondrial dysfunction are established AD hallmarks\", \"pmid\": \"PMID:31231128\"}, {\"claim\": \"WGCNA identifies reproducible co-expression patterns in brain transcriptomics\", \"pmid\": \"PMID:30617273\"}, {\"claim\": \"Entorhinal cortex, hippocampus, and PFC show early AD vulnerability\", \"pmid\": \"PMID:26753650\"}], \"evidence_against\": [{\"claim\": \"Synaptic genes are consistently downregulated in AD transcriptomic meta-analyses\", \"pmid\": \"PMID:30944315\"}, {\"claim\": \"Mitochondrial OXPHOS is impaired (reduced complex I/IV activity), not upregulated in AD proteomics\", \"pmid\": \"PMID:29353825\"}, {\"claim\": \"Bulk tissue RNA-seq cannot resolve cell-type-specific contributions\", \"pmid\": \"PMID:31270457\"}, {\"claim\": \"Similar synaptic-mitochondrial disruption occurs in PD, FTD, and normal aging\", \"pmid\": \"PMID:31542274\"}, {\"claim\": \"WGCNA modules frequently fail replication due to batch effects and sample heterogeneity\", \"pmid\": \"PMID:32929376\"}]}, {\"title\": \"Exosome-Mediated Tau Spreading Module\", \"description\": \"Tau pathology spreads via neuron-derived exosomes containing aggregated tau, with specific loading mechanisms (sumoylation, kinases) and uptake via LRP1 receptor on recipient neurons. This pathway explains propagation patterns in human AD brain.\", \"target_gene\": \"Rab27a, nSMase2, LRP1, tau\", \"composite_score\": 0.35, \"evidence_for\": [{\"claim\": \"Exosomes containing tau are detectable in AD patient CSF\", \"pmid\": \"PMID:28467893\"}, {\"claim\": \"Exosome-mediated tau transfer demonstrated in cell culture models\", \"pmid\": \"PMID:27144255\"}, {\"claim\": \"Inhibition of exosome release reduces tau spreading in mouse models\", \"pmid\": \"PMID:28389758\"}], \"evidence_against\": [{\"claim\": \"Tau-targeted antibodies semorinemab and gosuranemab failed Phase II targeting extracellular tau\", \"pmid\": \"PMID:34758345\"}, {\"claim\": \"GW4869 (nSMase2 inhibitor) has poor PK and does not cross BBB\", \"pmid\": \"unavailable\"}, {\"claim\": \"LRP1 knockout causes embryonic lethality and cognitive deficits in mice\", \"pmid\": \"PMID:26305630\"}, {\"claim\": \"Exosome biology is not disease-specific; blocking affects immune surveillance and synaptic function\", \"pmid\": \"PMID:33230315\"}]}], \"synthesis_summary\": \"Two hypotheses regarding molecular mechanisms in Alzheimer's disease were evaluated. The Conserved Synaptic-Mitochondrial Module hypothesis proposes coordinated upregulation of synaptic and mitochondrial genes across vulnerable brain regions, but faces significant challenges: bulk tissue RNA-seq cannot resolve cell-type contributions, established AD transcriptomics show synaptic genes are downregulated rather than upregulated, and the same pattern occurs in",
  "tokens_used": "802"
}